Skip to content

Contact +44 (0) 20 7060 7474 email us

Sales & Marketing

The Scandinavian Pharmaceutical Market Outlook to 2013

Policy environment, market structure, pipeline analysis, growth opportunities

Publication Date March 2009
Publisher Business Insights
Product Type Report
Pages 182
ISBN Number not applicable
Product Code RBI00200

Price

£2,025.00
approximately: $3,066 | €2,260

pdf

Buy Now

Order above formats by FAX

Order by Fax

Summary

The Scandinavian Pharma Market Outlook to 2013: Policy environment, market structure, pipeline analysis and growth opportunities

The Scandinavian healthcare system and pharmaceutical market is well regulated, with the state bearing responsibility for a large proportion of an individual's pharmaceutical expenses. Solidarity and equality are the ideological basis of these welfare states, and a significant public commitment exists towards ensuring access to high quality health care for all citizens. Sweden and Denmark have been the two biggest pharma and biotech markets in Scandinavia, while regional players such as Novo Nordisk have laid the foundations for this industry in the region.

'The Scandinavian Pharmaceutical Market Outlook to 2013' is a report published by Business Insights that explores the healthcare systems and policy environments of Denmark, Norway, Sweden and Finland. This report examines the region's market potential by assessing historic epidemiological data, sales trends, competitive intelligence and clinical data across each major country. The growth drivers of the region are identified and forecasts for major prescription drugs and markets are provided for the period 2009-13. The competitive landscape of the Scandinavian market is also evaluated, with the region's five leading companies being assessed based upon their marketed product portfolios and R&D pipelines in order to forecast their future competitive positions.

Key Findings

The Scandinavian pharma market recorded sales of $10.1bn in 2007, a 16% increase over 2006. Sweden had the largest market share (38%), followed by Finland (23%), Denmark (22%), and Norway (17%). These countries possess developed infrastructures, advanced technologies, R&D support and business friendly cultures. Pfizer led the Scandinavian market in 2007 with sales of $696m, a 6.3% increase over 2006.

Pfizer has a significant presence in all four Scandinavian markets and in the leading therapeutic areas of the region. Drugs for the treatment of CNS disorders are the largest product class in Scandinavia, with a market share of 20.7% in 2007. Cancer and cardiovascular diseases are the next largest therapeutic categories in the region.

Well-developed biotech and life sciences clusters across the Scandinavian region enable world-class research and provide pools of well-educated personnel and versatile facilities to support start-up companies.

Parallel trade has become a major concern for the profitability of Scandinavia-based Pharma companies in recent years. Factors driving this include lower prescription drug expenditures sought by payors and parallel traders' strategies benefit from price differentials for drugs across different countries.

Use this report to...

  • Compare the healthcare markets of key Scandinavian countries with this report's macroeconomic analysis of infrastructure, per capita health expenditure and Pharma sales growth vs. GDP growth across Sweden, Finland, Denmark and Norway.
  • Understand how healthcare policy environments vary across the region with this report's examination of drug approval processes, pricing regulations and reimbursement policies in each major country.
  • Identify which indications have the greatest potential to provide franchise growth with this report's evaluation of major therapy/sub-therapy areas and leading brands, including forecast sales over the period 2009-2013.
  • Measure the performances and prospects of leading companies in the Scandanavian area with this report's strategic analysis of leading pharma corporations based on sales focus by drug class, currently marketed products and R&D pipeline portfolios.

Explore issues including...

The threat to EU health spending. Pharma activity in the Scandinavian market is focused around cost containment, but in recent years the consumption of generics and parallel imports has slowly increased. A new pricing regime linked to other European countries has also had a moderating effect on price levels in Scandinavian countries over recent years.

Higher licensing deal values. Competition for promising projects (particularly drugs that have established solid proof-of-concept data) has not only boosted the deal values overall, but also increased the quantity and average value of deals in the early stages of product development.

Parallel trade influencing pricing. The prevalence of parallel trade is having a significant impact upon state expenditure on drugs and consumer prices. In Sweden, parallel imports have been included as substitutable products in accordance with the generic substitution policy, giving significant boost to parallel imported products in the country.

Support for generic substitution of patented drugs. A report by the National Trade Estimate of the United States Trade Representative (USTR) made special mention of Finland, due to the country's Pharma Pricing Board not always waiting for the expiry of the analogous process patent before taking action.

Discover...

  • What will be the major growth drivers in the Scandinavian pharma market over 2009-13?
  • Which companies were the winners and losers in the Scandinavian pharma market in 2007?
  • Which companies will become key players over 2009 -13?
  • Which products will be affected by generic competitors over the period 2009-13?
  • Which pipeline products will be the growth drivers of the future?
  • Which therapy areas and indications have the highest market potential over 2009-13?
  • How will the Scandinavian pharma market's competitive landscape change by 2013?

Contents

  • The Scandinavian pharmaceutical market outlook to 2013
    • Executive Summary
    • Scandinavia - An overview
    • Healthcare in Scandinavia
    • The pharmaceutical industry in Scandinavia
    • Key players in the Scandinavian pharmaceutical market
    • An overview of leading pipeline compounds
  • Chapter 1 Scope and methodology
    • Scope
    • Methodology
  • Chapter 2 Scandinavia - An overview
    • Summary
    • Introduction
    • Population profile
    • Disease burden
    • Macroeconomic comparison of countries
    • Infrastructure
    • Healthcare Spend
    • Pharmaceutical sales growth
  • Chapter 3 Healthcare in Scandinavia
    • Summary
    • Introduction
    • Pharmaceutical marketing authorization in the EEA
    • The policy environment - Sweden
    • The policy environment - Finland
    • The policy environment - Denmark
    • The policy environment - Norway
    • Parallel trade in Scandinavia
  • Chapter 4 The pharmaceutical industry in Scandinavia
    • Summary
    • Introduction
    • Key Events
    • Economic threats to EU health budgets
    • Structural changes in the pharmaceutical industry
    • Increasing licensing deal values
    • Increasing importance of the emerging markets
    • Therapy area analysis
    • Therapy area sales forecast
    • Sweden
    • Finland
    • Denmark
    • Norway
    • Leading brands
    • Leading Scandinavian brands sales forecast
    • Sweden
    • Finland
    • Denmark
    • Norway
    • Leading players
    • Leading players sales forecast
    • Sweden
    • Finland
    • Denmark
    • Norway
  • Chapter 5 Key players of the Scandinavian pharmaceutical market
    • Summary
    • Introduction
    • Analysis of the leading Scandinavian market players
    • Pfizer
    • Overview
    • Sales focus by leading drug classes
    • Marketed product portfolio
    • Pfizer's pipeline focus
    • Strategic growth analysis
    • AstraZeneca
    • Overview
    • Sales focus by leading drug classes
    • Marketed product portfolio
    • AstraZeneca's pipeline focus
    • Strategic growth analysis
    • Novartis
    • Overview
    • Marketed product portfolio
    • Novartis's pipeline focus
    • Strategic growth analysis
    • GSK
    • Overview
    • GSK's pipeline focus
    • Strategic growth analysis
    • Johnson & Johnson
    • Overview
    • Marketed product portfolio
    • J&J's pipeline focus
    • Strategic growth analysis
    • Leading Scandinavian pharmaceutical and biotechnology companies
    • Active Biotech
    • BioInvent
    • Strategic collaborations
    • Pipeline
    • Biotie Therapies
    • Diamyd
    • Pronova BioPharma
  • Chapter 6 An overview of leading pipeline compounds
    • Summary
    • Introduction
    • Leading drugs in development
    • Profiles of key pipeline products
    • Drugs in registration
    • Zactima
    • Axitinib
    • Paliperidone palmitate
    • Drugs in phase III clinical studies
    • Laquinimod
    • Diamyd
    • Eprotirome
    • Promacta
    • Menveo
    • Xarelto
    • Pipeline Forecast
  • Chapter 7 Scandinavian pharmaceutical market outlook - Summary findings
    • An attractive market:
    • Resistors to growth in Scandinavia
  • Chapter 8 Appendix
    • IMS Data
    • Anatomical Therapeutic Classification (ATC)
    • C: Cardiovascular system
    • N: Nervous system
    • A: Alimentary tract and metabolism
    • L: Antineoplastic and immunomodulating agents
    • J: General anti-infectives systemic
    • R: Respiratory system
    • M: Musculo-skeletal system
    • G: Genito-urinary system and sex hormones
    • B: Blood and blood forming organs
    • D: Dermatologicals
    • T: Diagnostic agents
    • H: Systemic hormonal preparations
    • S: Sensory organs
    • V: Various
    • Licensing status as per IMS Health
    • Original brand
    • Other brand
    • Licensed brand
    • Patent N/A brands
    • Unbranded/ generic product
    • Glossary
    • Index
  • List of Figures
    • Figure 2.1: Demographic profile of Scandinavian countries
    • Figure 2.2: Comparison of healthcare expenditure across Scandinavian countries
    • Figure 2.3: GDP growth versus pharmaceutical sales growth, 2006-2007
    • Figure 4.4: Scandinavian pharmaceutical market share by country, 2007
    • Figure 4.5: Scandinavian pharmaceutical market sales by therapy area, US$m, 2007
    • Figure 4.6: Top ten sub-therapy areas in the Swedish pharmaceutical market, 2007 ($m)
    • Figure 4.7: Top ten sub-therapy areas in the Finnish pharmaceutical market, 2007 ($m)
    • Figure 4.8: Top ten sub-therapy areas in the Danish pharmaceutical market, 2007 ($m)
    • Figure 4.9: Top ten sub-therapy areas in the Norwegian pharmaceutical market, 2007 ($m)
    • Figure 5.10: Market share of leading players in the Scandinavian market, 2007
    • Figure 5.11: Pfizer's Scandinavian market sales by therapy area, 2007, $m
    • Figure 5.12: AstraZeneca's Scandinavian market sales by therapy area, 2007, $m
    • Figure 5.13: Novartis's Scandinavian market sales by therapy area, 2007
    • Figure 5.14: GSK's Scandinavian market sales by therapy area, 2007
    • Figure 5.15: J&J's Scandinavian market sales by therapy area, 2007
    • Figure 6.16: Leading late-stage R&D products, 2008
    • Figure 6.17: Scandinavian markets' pipeline of biotechnology products by stage of development, 2008
    • Table 2.1: Forecast epidemiology of common disorders in Sweden, 2007-2013
    • Table 2.2: Forecast epidemiology of common disorders in Finland, 2007-2013
    • Table 2.3: Forecast epidemiology of common disorders in Denmark, 2007-2013
    • Table 2.4: Forecast epidemiology of common disorders in Norway, 2007-2013
    • Table 3.5: Reimbursement of pharmaceutical expenditure in Denmark
    • Table 3.6: Rates of reduction on annual sale of pharmaceutical products
    • Table 4.7: Scandinavian pharmaceutical market sales by ATC code, US$m, 2007-2013
    • Table 4.8: Sweden's pharmaceutical market by therapy area sales, US$m, 2007
    • Table 4.9: Finland's pharmaceutical market by therapy area sales, 2007, ($m)
    • Table 4.10: Denmark's pharmaceutical market by therapy area sales, 2007
    • Table 4.11: Norway's pharmaceutical market by therapy area sales, 2007
    • Table 4.12: Leading brands in the Scandinavian pharmaceutical market, 2007
    • Table 4.13: Leading brands sales forecast, 2007-13
    • Table 4.14: Leading brands in the Swedish pharmaceutical market, 2007
    • Table 4.15: Leading brands in the Finnish pharmaceutical market, 2007
    • Table 4.16: Leading brands in the Danish pharmaceutical market, 2007
    • Table 4.17: Leading brands in the Norwegian pharmaceutical market, 2007
    • Table 4.18: Leading companies in the Scandinavian pharmaceutical market, 2007
    • Table 4.19: Leading companies in the Scandinavian pharmaceutical market, sales forecast 2007- 2013
    • Table 4.20: Leading companies in the Swedish pharmaceutical market, 2007
    • Table 4.21: Leading companies in the Finnish pharmaceutical market, 2007
    • Table 4.22: Leading companies in the Danish pharmaceutical market, 2007
    • Table 4.23: Leading companies in the Norwegian pharmaceutical market, 2007
    • Table 5.24: Pfizer's leading brands in Scandinavia, 2007
    • Table 5.25: AstraZeneca's leading brands in Scandinavia, 2007
    • Table 5.26: Novartis's leading brands in Scandinavia, 2007
    • Table 5.27: GSK's leading brands in Scandinavia, 2007
    • Table 5.28: J&J's leading brands in Scandinavia, 2007
    • Table 5.29: BioInvents major collaborations
    • Table 6.30: An overview of Zactima
    • Table 6.31: An overview of axitinib
    • Table 6.32: An overview of Paliperidone palmitate
    • Table 6.33: An overview of Laquinimod
    • Table 6.34: An overview of Diamyd
    • Table 6.35: An overview of Eprotirome
    • Table 6.36: An overview of Promacta
    • Table 6.37: An overview of Menveo
    • Table 6.38: An overview of Xarelto
    • Table 6.39: Forecast sales of pipeline compounds, 2007-2013